Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer

Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer

  • CN 104,379,163 A
  • Filed: 06/07/2013
  • Published: 02/25/2015
  • Est. Priority Date: 06/08/2012
  • Status: Active Application
First Claim
Patent Images

1. a method for overmedication proliferative disorders, it comprises and gives therapeutic combination with combination preparation or alternately to mammal, and wherein said therapeutic combination comprises:

  • The GDC-0032 with following structure for the treatment of effective dose;

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×